# Manus Rogan

> Manus Rogan is a Series B investor at Fountain Healthcare Partners backing Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Fountain Healthcare Partners](https://shizune.co/investors/profile/fountain-healthcare-partners)
- Location: Dublin, Ireland
- Total investments: 14
- Last investment: Feb 2024
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/manus-rogan/2/152/ab9
- Website: http://www.fh-partners.com/team

Manus Rogan is a Series B investor at Fountain Healthcare Partners in Dublin focused on Biotechnology and Medical. Manus Rogan is based out of Dublin, Dublin and is the Co-Founder & Managing Partner of Fountain Healthcare Partners. Manus previously worked at GlaxoSmithkline as a product development. Manus Rogan attended the Trinity College Dublin.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 36% |
| Medical | 4 | 29% |
| Health Care | 4 | 29% |
| Medical Device | 2 | 14% |
| Pharmaceutical | 2 | 14% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 21% |
| Series A | 2 | 14% |
| Post-IPO Equity | 2 | 14% |
| Series C | 1 | 7% |
| Private Equity | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mainstay Medical | Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $125M | Private Equity | Feb 26, 2024 |  |
| Neuromod Devices | Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $16.6M | Series B | Apr 13, 2023 |  |
| Mainstay Medical | Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $108M | Private Equity | Feb 16, 2021 |  |
| Neuromod Devices | Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $11.5M | Series B | Oct 20, 2020 |  |
| Priothera | Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic HematopoieticStem Cell Transplantation (HSCT) in these patients. | $35.4M | Series A | Oct 12, 2020 |  |
| Neuromod Devices | Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $8.8M | Series A | Sep 26, 2019 |  |
| Mainstay Medical | Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $32.9M | Post-IPO Equity | Feb 15, 2018 |  |
| Opsona | Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004,Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland. | $3.3M | Series C | Oct 02, 2013 |  |
| Opsona | Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004,Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland. | $36.2M | Series C | Apr 29, 2013 |  |
| Mainstay Medical | Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $20M | Series B | Sep 25, 2012 |  |

10 of 14 investments shown.

## Co-investors
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 5 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 3 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 2 deals together
- [KCK](https://shizune.co/investors/profile/kck) — VC Fund, 2 deals together
- [Kreos Capital](https://shizune.co/investors/profile/kreos-capital) — VC Fund, 2 deals together

## About Fountain Healthcare Partners

VC Fund · Dublin, Ireland

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

4 contacts available at Fountain Healthcare Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Aidan King | Co-Founder & Managing Partner | https://shizune.co/investors/profile/aidan-king |
| Ena Prosser | Partner | https://shizune.co/investors/profile/ena-prosser |
| Justin Lynch | Partner & CFO | https://shizune.co/investors/profile/justin-lync |
| Manus Rogan | Co-Founder & Managing Partner | https://shizune.co/investors/profile/manus-rogan |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Manus Rogan invest in?

Manus Rogan invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Manus Rogan last invest?

The most recent investment recorded for Manus Rogan closed in Feb 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co